Literature DB >> 21211829

Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix.

M L Tornesello1, S Losito, G Benincasa, F Fulciniti, G Botti, S Greggi, L Buonaguro, F M Buonaguro.   

Abstract

OBJECTIVE: Human papillomavirus (HPV) genotypes have been extensively studied in uterine cervix squamous cell carcinoma and HPV16 variants have been found to be associated with increased cancer risk, but few reports have been published on genotype distribution and HPV16 variant prevalence in adenocarcinoma tumors. The objective of this study was to analyze viral genotypes and HPV16 intratypic variants in cervical adenocarcinoma and squamous cell carcinoma of Italian women.
METHODS: A total of 39 invasive adenocarcinoma and 132 squamous cell carcinoma were reviewed and classified according to the modified WHO classification. HPV sequences were detected by nested PCR, using the broad spectrum consensus-primer pairs MY09/MY11 and the GP5+/GP6+ system, and genotyped by nucleotide sequence analysis. The HPV16-positive cases were amplified with E6-specific oligonucleotides and amplimers subjected to direct nucleotide sequence for variant identification.
RESULTS: The prevalence rate of any HPV infection was 72% in adenocarcinoma, and 85% in cervical squamous cell carcinoma. Among the 140 HPV-positive cancer cases, a total of nine mucosal HPV genotypes (HPV16, 18, 31, 33, 35, 39, 45, 58, 82) epidemiologically classified as carcinogenic or probably carcinogenic viruses were identified. The HPV type 16 was the most common viral type representing 64% and 73% of all infections in adenocarcinoma and squamous cell carcinoma, respectively. The E6 nucleotide sequence analysis of HPV16 isolates allowed the identification of Asian American (AA) variants in 33% of adenocarcinoma and in 20% of squamous cell carcinoma suggesting their stronger association with cancer of glandular origin.
CONCLUSION: These results suggest that HPV16 has a high prevalence in both invasive adenocarcinoma and squamous cell carcinoma from Italian patients. Moreover this study confirms previous observations, summarized in a systematic review of the literature, on the increased cancer risk of HPV16 AA class in adenoglandular cancer, possibly related to their more oncogenic behavior compared to HPV16 European variants.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21211829     DOI: 10.1016/j.ygyno.2010.12.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

Review 1.  Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfalls.

Authors:  David C Wilbur
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

2.  Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Okame; Atsumi Kojima; Norihiro Teramoto; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara; Takayoshi Nogawa
Journal:  Int J Clin Oncol       Date:  2015-12-22       Impact factor: 3.402

3.  Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens.

Authors:  Yaoyao Guan; Patti E Gravitt; Roslyn Howard; Yolanda J Eby; Shaoming Wang; Belinda Li; Changyan Feng; You-Lin Qiao; Philip E Castle
Journal:  J Virol Methods       Date:  2013-01-29       Impact factor: 2.014

4.  Genomic differences in the background of different severity in juvenile-onset respiratory papillomatoses associated with human papillomavirus type 11.

Authors:  Tamás Gáll; Andrea Kis; Tímea Zsófia Tatár; Gábor Kardos; Lajos Gergely; Krisztina Szarka
Journal:  Med Microbiol Immunol       Date:  2013-05-07       Impact factor: 3.402

5.  Effect of HPV 16 E6 Oncoprotein Variants on the Alterations of the Proteome of C33A Cells.

Authors:  Olga Lilia Garibay-Cerdenares; Luz Victoria Sánchez-Meza; Sergio Encarnación-Guevara; Magdalena Hernández-Ortíz; Gabriel Martínez-Batallar; Francisco Israel Torres-Rojas; Miguel Ángel Mendoza-Catalán; Oscar Del Moral-Hernández; Marco Antonio Leyva-Vázquez; Berenice Illades-Aguiar
Journal:  Cancer Genomics Proteomics       Date:  2021-04-23       Impact factor: 4.069

6.  Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women.

Authors:  Zineb Qmichou; Meriem Khyatti; Mohamed Berraho; My Mustapha Ennaji; Laila Benbacer; Chakib Nejjari; Noureddine Benjaafar; Abdellatif Benider; Mohammed Attaleb; Mohammed El Mzibri
Journal:  BMC Infect Dis       Date:  2013-08-16       Impact factor: 3.090

7.  Prevalence of HPV 16 and HPV 18 lineages in Galicia, Spain.

Authors:  Sonia Pérez; Ana Cid; Amparo Iñarrea; Mónica Pato; María José Lamas; Bárbara Couso; Margarita Gil; María Jesús Alvarez; Sonia Rey; Isabel López-Miragaya; Santiago Melón; María de Oña
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

Review 8.  HPV-Negative Cervical Cancer: A Narrative Review.

Authors:  Francesca Arezzo; Gennaro Cormio; Vera Loizzi; Gerardo Cazzato; Viviana Cataldo; Claudio Lombardi; Giuseppe Ingravallo; Leonardo Resta; Ettore Cicinelli
Journal:  Diagnostics (Basel)       Date:  2021-05-26

9.  Screening and detection of human papillomavirus (HPV) high-risk strains HPV16 and HPV18 in saliva samples from subjects under 18 years old in Nevada: a pilot study.

Authors:  Colton Flake; Jamal Arafa; Alex Hall; Eryn Ence; Katherine Howard; Karl Kingsley
Journal:  BMC Oral Health       Date:  2012-10-22       Impact factor: 2.757

10.  Epidemiology of Cervical Adenocarcinoma and Squamous Cell Carcinoma Among Women Living With Human Immunodeficiency Virus Compared With the General Population in the United States.

Authors:  Anne F Rositch; Kimberly Levinson; Gita Suneja; Analise Monterosso; Maria J Schymura; Timothy S McNeel; Marie-Josephe Horner; Eric Engels; Meredith S Shiels
Journal:  Clin Infect Dis       Date:  2022-03-09       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.